People | November 11, 2022
Biogen appoints Christopher Viehbacher as President and CEO
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
His experience covers a wide range of areas including advisory services in the field of accounting, taxation, corporate and commercial laws, and regulatory matters
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Plans to double its manufacturing footprint to bolster the growth
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Subscribe To Our Newsletter & Stay Updated
